Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Bumped Up to "Hold" by Wall Street Zen

Key Points

• Wall Street Zen upgraded Enanta Pharmaceuticals from “Sell” to “Hold,” while analysts overall maintain a “Moderate Buy” consensus with a $19.00 average price target.
• ENTA shares opened at $12.96, near their 50-day and 200-day moving averages, and have traded between $10.12 and $17.15 over the past year.
• Enanta reported a quarterly loss of $0.67 per share, missing estimates by $0.16, while revenue of $14.36 million also fell short of expectations; institutional investors own approximately 95% of the stock.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday, Wall Street Zen reports.

A number of other analysts have also commented on ENTA. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $12.96 on Friday. The business has a 50-day moving average of $13.13 and a 200-day moving average of $13.29. The company has a market capitalization of $377.40 million, a price-to-earnings ratio of -5.38 and a beta of 0.96. Enanta Pharmaceuticals has a 1 year low of $10.12 and a 1 year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The business had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -2.36 EPS for the current year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ENTA. Wellington Management Group LLP lifted its stake in Enanta Pharmaceuticals by 8.9% during the second quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company's stock worth $1,190,000 after purchasing an additional 6,673 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $314,000. Jupiter Topco LLC purchased a new position in Enanta Pharmaceuticals during the 2nd quarter valued at $53,252,000. ADAR1 Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the second quarter valued at about $19,603,000. Finally, Legal & General Group Plc purchased a new position in shares of Enanta Pharmaceuticals during the second quarter valued at about $41,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company's research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie's Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.